In the UK, diabetes mellitus affects around 3 million people, of whom over 90% have type 2 diabetes.1 Aims of treatment include minimising long-term complications (e.g. cardiovascular disease, blindness, chronic kidney disease, premature mortality) and avoiding unwanted effects of treatment (e.g. severe hypoglycaemia, weight gain).2 Management of diabetes includes patient support and education; addressing symptoms; lifestyle modification; targeting associated risk factors for cardiovascular disease; and surveillance for, and management of, complications including treatment-related hypoglycaemia.2 ▼Dapagliflozin (Forxiga) belongs to a new class of oral glucose-lowering drugs that inhibit renal glucose reabsorption and promote glycosuria.3 It is licensed in the UK in adults with type 2 diabetes as monotherapy when diet and exercise alone do not provide adequate glycaemic control and who are unable to tolerate metformin; or, as add-on therapy, with other glucose-lowering agents including insulin, when these, with diet and exercise, do not provide adequate glycaemic control.3 The company's advertising materials claim that dapagliflozin provides a “novel method of controlling excess glucose” with “secondary benefit of weight loss”. Here, we review the evidence for the use of dapagliflozin in the management of type 2 diabetes mellitus.
|Journal||Drug and Therapeutics Bulletin|
|Publication status||Published - 12 Sept 2013|